Document is current

Article History

Received: 8 April 2020

Accepted: 6 May 2020

First Online: 29 May 2020

Compliance with ethical standards

:

: BAM: discloses payment for consulting with Bayer, Astellas, Astra Zeneca, Seattle Genetics, Exelixis, Nektar, Pfizer, Janssen, Genentech and EMD Serono. He received research support to Dana Farber Cancer Institute (DFCI) from Bristol Myers Squibb, Calithera, Exelixis, Seattle Genetics.RF: no competing interests.MG reports other from Medimmune, other from Merck, other from BMS, other from Amgen, other from Tesaro, other from Beigene, other from ABBVIE, other from Aeglea, personal fees and other from Agenus, other from Arcus, other from Astex, other from BluePrint, other from Calithera, other from CellDex, other from Corcept, other from Clovis, other from Eli Lilly, other from Endocyte, other from Five Prime, other from Genocea, other from Neon, other from Plexxicon, personal fees and other from Imaging Endpoints, other from Revolution Medicine, other from Seattle Genetics, other from Serono, other from SynDevRx, other from Toleron, personal fees and other from Tracon, personal fees and other from Deciphera, personal fees and other from Salarius, outside the submitted work.NA discloses payment for consultancy to Astellas, Astra Zeneca, BMS, Bayer, Clovis, Eisai, Exelixis, EMD Serono, Ely Lilly, Foundation Medicine, Genentech, Janssen, Merck, Novartis, Nektar, Pfizer, Pharmacyclics.SG reports grants and personal fees from Bayer, grants and personal fees from BMS, grants from Novartis, personal fees from Exelixis, personal fees from Janssen, grants and personal fees from Corvus, personal fees from Genentech, personal fees from Sanofi/ Genzyme, grants and personal fees from Pfizer, grants from Acceleron, grants from Merck, grants from Agensys, grants from Eisai, personal fees from EMD Serono, outside the submitted work.DIQ discloses payment for consulting with Bayer, BMS, Exelixis, Merck, Novartis and Pfizer.MR, TH and TK own stock and are employees of Celldex Therapeutics, Inc.TKC discloses payment for consulting to Analysis Group, AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol-Myers Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Heron Therapeutics, Lilly, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, Michael J. Hennessy (MJH) Associates, Inc. (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology. He received research support to DFCI from Analysis Group, AstraZeneca, Alexion, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Sanofi/Aventis, Takeda.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.